Loading...

Home
ETF
IVVD

IVVD

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

IVVD News

Invivyd Chairman to Speak at Health Summit

20h agoNewsfilter

Invivyd Reports Progress in Late-Stage Trial for COVID-19 Therapy VYD2311

Apr 09 2026seekingalpha

Invivyd Announces Progress in COVID-19 Study and New Measles Antibody Candidate

Apr 09 2026Newsfilter

Invivyd Launches National Antibody Education Campaign

Apr 07 2026Newsfilter

Invivyd Grants Stock Options to New Employees

Apr 06 2026Newsfilter

BETA Technologies Reports Disappointing Q4 Results

Mar 09 2026Benzinga

Invivyd Q4 2025 Earnings Call Highlights

Mar 05 2026seekingalpha

Invivyd Reports Q4 2025 Financial Results and Clinical Trial Updates

Mar 05 2026Newsfilter

Invivyd Set to Announce FY Earnings with Significant Growth Expectations

Mar 04 2026seekingalpha

Invivyd Aligns with FDA on LIBERTY Phase 3 Trial for VYD2311

Feb 03 2026seekingalpha

Invivyd Launches LIBERTY Clinical Trial for VYD2311

Feb 03 2026Newsfilter

Invivyd Initiates Phase 2 Trial for VYD2311 Targeting Long COVID Patients

Jan 20 2026Newsfilter

Invivyd Reports Q4 2025 Revenue of $17.2M, Up 25% Year-over-Year

Jan 08 2026Globenewswire

Invivyd Receives FDA Fast Track Designation for VYD2311 Vaccine

Dec 23 2025Globenewswire

Invivyd Initiates Phase 3 DECLARATION Trial for VYD2311 with 1770 Participants

Dec 23 2025Globenewswire

BTIG Initiates Buy Rating on Invivyd Inc with $10 Price Target

Dec 22 2025Benzinga